Exact Sciences, a molecular-daignostics company, has reported revenues of $1.4m for the third quarter of 2010, compared to $1.3m during the same period of 2009.
Exact Sciences has posted a net loss of $3.4m, or $0.08 per share, for the third quarter of 2010, compard to a net loss of $1m, or $0.03 a share, for the same period of 2009.
Operating expenses were $4.7m for the third quarter of 2010, compared to $2.3m for the same period of 2009.
For the first nine months ended 30 September 2010, Exact Sciences has posted total revenues of $4m, compared to total revenues of $3.5m for the same period of 2009.
For the first nine months ended 30 September 2010, net loss was $8m, or $0.21 per share, compared to $7.3m, or $0.23 per share, for the same period of 2009.
Operating expenses for the first nine months of 2010 were $12m, compared to $10.9m for the same period of 2009.
Exact Sciences president and CEO Kevin Conroy said that the company’s primary focus during the third quarter was the completion of validation study, a major milestone to bring to market an accurate, patient-friendly screening test that detects both pre-cancers and cancer.